Gamco Investors INC. ET AL reduced its position in shares of Masimo Co. (NASDAQ:MASI) by 5.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 112,000 shares of the medical equipment provider’s stock after selling 6,000 shares during the quarter. Gamco Investors INC. ET AL owned about 0.22% of Masimo worth $13,948,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. bought a new stake in Masimo during the 2nd quarter worth about $109,000. CIBC Asset Management Inc bought a new stake in shares of Masimo in the 3rd quarter valued at about $227,000. US Bancorp DE increased its stake in shares of Masimo by 36.9% in the 2nd quarter. US Bancorp DE now owns 1,980 shares of the medical equipment provider’s stock valued at $193,000 after acquiring an additional 534 shares during the last quarter. Personal Capital Advisors Corp bought a new stake in shares of Masimo in the 3rd quarter valued at about $251,000. Finally, Matisse Capital bought a new stake in shares of Masimo in the 2nd quarter valued at about $202,000. 83.22% of the stock is owned by hedge funds and other institutional investors.
Shares of MASI stock opened at $115.49 on Friday. The stock has a market capitalization of $6.09 billion, a PE ratio of 47.14, a P/E/G ratio of 2.70 and a beta of 1.11. Masimo Co. has a one year low of $80.69 and a one year high of $126.89.
Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Wednesday, October 31st. The medical equipment provider reported $0.71 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.02. The company had revenue of $210.58 million during the quarter, compared to analysts’ expectations of $207.62 million. Masimo had a return on equity of 20.29% and a net margin of 17.08%. Masimo’s revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.56 EPS. On average, sell-side analysts predict that Masimo Co. will post 2.92 earnings per share for the current year.
In related news, EVP Bilal Muhsin sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $117.75, for a total value of $2,355,000.00. Following the completion of the transaction, the executive vice president now directly owns 10,000 shares in the company, valued at approximately $1,177,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Joe E. Kiani sold 239,926 shares of the business’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $117.95, for a total value of $28,299,271.70. Following the completion of the transaction, the chief executive officer now owns 236,061 shares of the company’s stock, valued at $27,843,394.95. The disclosure for this sale can be found here. Insiders sold a total of 666,033 shares of company stock valued at $79,900,568 over the last quarter. 12.60% of the stock is owned by insiders.
MASI has been the subject of a number of recent analyst reports. Stifel Nicolaus upped their price target on Masimo from $112.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, October 2nd. BidaskClub cut Masimo from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 3rd. Needham & Company LLC initiated coverage on Masimo in a research note on Friday, September 14th. They issued a “buy” rating for the company. Piper Jaffray Companies upped their price target on Masimo to $120.00 and gave the company a “neutral” rating in a research note on Thursday, November 1st. Finally, Zacks Investment Research cut Masimo from a “buy” rating to a “hold” rating in a research note on Wednesday, August 1st. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Masimo currently has an average rating of “Buy” and a consensus price target of $114.40.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Further Reading: How does inflation affect different investments?
Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.